Genetic differences in HLA phenotypes were studied in coeliac disease to investigate why some patients do not react with mucosal damage after gluten challenge. Forty five children with coeliac disease and 16 with transitory gluten intolerance were typed; 76 subjects served as controls. HLA phenotypes in children with coeliac disease had significantly higher proportions of DR3/X and DR5/7 than controls (48-8% v 11-8% and 26-7% v 5.3%). Children with transitory gluten intolerance had lower DR3/X (43.8%) than children with coeliac disease and there were no DR5/7 phenotypes.
Coeliac disease has been recognised since 1888 when Samuel Gee first described the 'coeliac affection' as a disease entity with severe malabsorption and chronic diarrhoea combined with failure to thrive.' The typical hyperplastic villous atrophy of the proximal small intestine as a reaction to the toxic agent gluten2 is considered to be mediated initially by an immunological reaction of the T lymphocytes of the mucosal lamina propria. These are predominantly of the CD4+ type.3
Genetic control of this reaction is related to the major histocompatibility complex (MHC) region of chromosome 6, which encodes the MHC class I and class II molecules.4 5 In this way coeliac disease affects genetically susceptible individuals. Susceptibility to coeliac disease has also been associated with HLA-A8,6 7 HLA-DR,8-11 and HLA-DQ12 13 21 patients in whom the diagnosis of coeliac disease was made by the typical clinical picture at presentation without initial biopsy, followed by a gluten-free diet for at least two years and good clinical recovery, then subsequent gluten challenge with histological reaction after having an intestinal biopsy. They were considered to have permanent coeliac disease. In the 40 subjects of group II, the diagnosis of coeliac disease was based on the original ESPGAN criteria. After the establishment of the diagnosis, shown by clinical presentation and hyperplastic villous atrophy in the first biopsy, the patients recovered taking a glutenfree diet for a minimum of two years and a second biopsy was performed before a prospective gluten challenge. All patients with coeliac disease are part of a large number of patients (n>450) being followed up in the hospital.
GLUTEN CHALLENGE
A third biopsy was performed after an initial standardised gluten challenge in all patients by giving 0-5 g/kg of body weight/day of gluten in the form of a powder added to the otherwise gluten-free diet for one month. Patients with a morphologically normal mucosa were changed to a normal diet. All patients with a histologically normal mucosa of group II (16/40) were consecutively changed to a normal diet. They remained on a normal diet for [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] years. Control biopsies were performed every two years during the phenotypes DR3/X and DR5/5 was comparable in both but lowest for DR3/X. The patients with transitory gluten intolerance in our study group, however, showed lower DR3/X and no DR5/7 phenotypes.
Discussion
The definition of the permanence of coeliac disease has undergone some modifications and changes over the last 25 years. The first ESPGAN criteria of 1969, proposed at the Interlaken meeting, defined coeliac disease as (a) a structurally abnormal mucosa when taking a diet containing gluten, (b) clear improvement ofvillous structure when taking a gluten-free diet, and (c) deterioration of the mucosa during challenge. 14 The revision of these criteria in 1990 stated that the diagnosis of coeliac disease does not require further confirmation if the initial diagnosis is based firstly on the appearance of flat small intestinal mucosa with the histological features of hyperplastic villous atrophy and, secondly, on unequivocal and full clinical remission after withdrawal of gluten from the diet.21
Exceptions to this rule are patients in whom the initial diagnosis was established before the age of 2 years and teenagers who tend to abandon the diet. In our study all patients have been challenged with gluten in a prospective manner regardless of the age of onset of coeliac disease. Sixteen subjects out of 61 did not react to gluten challenge and followed a normal diet afterwards for 5-15 years. They were considered to have suffered from transitory gluten intolerance. The number of patients with transitory gluten intolerance was thought to be not unusual because of the large number of proved coeliac patients (n>450) in the hospital. Genetic similarities with coeliac disease or normal controls would be of great help to classify them into either group, because the HLA-DQ genes of patients with coeliac disease are identical to those found among healthy subjects. 
